IG
BIO icon

ING Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

ING Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.1M Buy
112,700
+22,700
+25% +$6.44M 0.16% 112
2026
Q1 		$25.1M Buy
+90,000
New +$25.9M 0.15% 113
2024
Q2 		– Sell
-2,868
Closed -$992K – 547
2024
Q1 		$992K Sell
2,868
-3,598
-56% -$1.18M 0.01% 514
2023
Q4 		$2.09M Buy
6,466
+6,344
+5,200% +$1.99M 0.02% 400
2023
Q3 		$43.7K Buy
+122
New +$47.1K ﹤0.01% 552
2023
Q2 		– Sell
-3,659
Closed -$1.75M – 552
2023
Q1 		$1.75M Sell
3,659
-2
-0.1% -$936 0.02% 379
2022
Q4 		$1.54M Buy
+3,661
New +$1.48M 0.02% 387
2022
Q3 		– Sell
-1,873
Closed -$927K – 418
2022
Q2 		$927K Sell
1,873
-1,555
-45% -$810K 0.01% 459
2022
Q1 		$1.93M Sell
3,428
-4,092
-54% -$2.47M 0.02% 400
2021
Q4 		$5.68M Buy
7,520
+1,016
+16% +$760K 0.05% 253
2021
Q3 		$4.85M Buy
6,504
+4,734
+267% +$3.55M 0.06% 200
2021
Q2 		$1.14M Buy
1,770
+343
+24% +$209K 0.02% 425
2021
Q1 		$815K Sell
1,427
-1
-0.1% -$592 0.02% 426
2020
Q4 		$832K Buy
1,428
+955
+202% +$544K 0.02% 435
2020
Q3 		$244K Buy
+473
New +$240K 0.01% 444
2018
Q4 		– Sell
-3,063
Closed -$959K – 707
2018
Q3 		$959K Sell
3,063
-39
-1% -$12.1K 0.02% 372
2018
Q2 		$895K Buy
+3,102
New +$857K 0.02% 341
2018
Q1 		– Sell
-2,310
Closed -$551K – 736
2017
Q4 		$551K Buy
2,310
+587
+34% +$142K 0.01% 477
2017
Q3 		$383K Sell
1,723
-809
-32% -$182K 0.01% 601
2017
Q2 		$573K Buy
+2,532
New +$552K 0.01% 442

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ING Group's BIO Position: Q2 2026 in Review

ING Group increased its Bio-Rad Laboratories Class A (BIO) stake by 25% in Q2 2026, buying an estimated $6.44M and bringing the position to 112,700 shares worth $33.1M. The position accounts for 0.16% of the portfolio, ranked #112.

ING Group first reported a position in BIO in Q2 2017 and has held it in 20 quarters since. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • ING Group held 112,700 shares of Bio-Rad Laboratories Class A worth $33.1M as of Q2 2026.
  • ING Group bought 22,700 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $6.44M.
  • Bio-Rad Laboratories Class A made up 0.16% of ING Group's portfolio in Q2 2026, its #112 holding.
  • ING Group first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and has held it in 20 quarters since.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.